Societa' Farmaceutici Italia

Farmitalia Carlo Erba

Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Amplifon S.p.a.

Farmitalia Societa Farmaceutica Italia

Luigi Bernardi

Federico Maria Arcamone

Antonino Suarato

Piero Melloni

Paolo Masi

Aldemio Temperilli

Bianca Patelli

Luisa Quadri

Giovanni B Falconi

Patrizia Ferrari

Giuliana Arcari

Germano Bosisio

Loredana Valentino

Giuseppe Bianchi

Patricia Salvati

Sergio Mantegani

Maurizio Foglio

Alessandro Rossi

Mauro Gobbini

Aurelio Di Marco

Pietro Giardino

Carlo Elli

Gabriella Traquandi

Alberto Cerri

Mara Ferrandi

Daniela Ruggieri

Laura Chiodini

Giorgio Palamidessi

Alfredo Glasser

Giovanni Franceschi

Marco Frigerio

Enrico Di Salle

Alberto Bonsignori

Ugo Scarponi

Lorenzo Pegrassi

Elena Folpini

Marina Mauro

Rosella Ferrari

Sergio Penco

Nicoletta Almirante

Enzo Brambilla

Marco Torri

Ettore Lazzari

Giuseppe Mazzini

Fulvio Luini

Giovanni Francheschi

Enzo Beacco

Osvaldo Sapini

Rosanna Eccel

Gloria Padoani

Roberto Villa

Innocenzio Sinatra

Gian Carlo Fregnan

Severina Coda

Giselbert Karl Suchowsky, Deceased

Aurelia Di Marco

Maria L Malnati

Monica Florio

17-Aryl -5.alpha.,14.beta.-androstane, androstene and androstadiene derivatives of formula (I): ##STR1## wherein the symbol --- represents a single or a double bond; when the double bond is not present in the 4 or 5 position, the hydrogen in position 5 has the .alpha. configuration; Y is oxygen or guanidinoimino, when --- in position 3 is a double bond; Y is hydroxy, OR.sup.2 or SR.sup.2, when in position 3 is a single bond and has an .alpha. or .beta. configuration; R is a substituted or unsubstituted aryl ring; and R.sup.1 is hydrogen, methyl, ethyl or n-propyl substituted by OH or NR.sup.4 R.sup.5.

17-aryl and 17-heterocyclyl-14.beta.-5.alpha.-androstane, androstene and

Cyclopentanperhydrophenantren-17.beta.-(3-furyl)-3-derivatives and pharmaceutical compositions containing same for the treatment of cardiovascular disorders such as heart failure and hypertension, are disclosed.

Cyclopentanperhydrophenanthren-17.beta.-(3-furyl)-3-derivatives and

The present invention relates to a group of 17-(3-furyl)- and (4-pyridazinyl) 5.beta.,14.beta.-androstane derivatives, active on the cardiovascular system, to processes for their preparation and to pharmaceutical compositions containing same for the treatment of cardiovascular disorders such as heart failure and hypertension.

17-(3-furyl)-5.beta., 14.beta.-androstane derivatives active on the

Present invention relates to a group of 17-(4-pyridazinyl)-5.beta.,14.beta.-androstane derivates active on the cardiovascular system and to pharmaceutical compositions containing same.

17-(4-pyridazinyl) -5.beta., 14.beta.-androstane derivatives active on

17-aryl and heterocyclyl-5.beta.,14.beta.-androstane compounds having the formula (I) ##STR1## wherein R is an aryl ring or a saturated or unsaturated heterocyclic ring are active on the cardiovascular system and are useful in treating cardiovascular disorders.

17-Aryl and 17-heterocyclyl-5.beta.,14.beta.-androstane derivatives

17-Heterocyclyl-5.alpha.-14.beta.-androstane, androstene and androstadiene of formula (I): ##STR1## wherein: Y is oxygen or guanidinoimino, when a double bond exists at position 3; Y is hydroxy, OR.sup.2 or SR.sup.2, when a single bond exists at position 3; R is a saturated or unsaturated mono- or biheterocyclic ring, containing one or more heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, unsubstituted or substituted by one or more of halogen, hydroxymethyl, alkoxy, amino, alkylamino, dialkylamino, cyano, nitro, sulfonamido, C.sub.1 -C.sub.6 lower alkyl or COR.sup.3 ; and R.sup.1 is hydrogen, methyl, ethyl or n-propyl substituted by OH or NR.sup.4 R.sup.5.

17-heterocyclyl-14beta-5alpha-androstane, androstene and androstadiene

The present invention relates to new 17-hydrazonomethyl- and 17-hydrazono-14.beta.-hydroxy-5.beta.-androstane derivatives active on the cardiovascular system, to a process for their preparation and to pharmaceutical compositions containing same for the treatment of cardiovascular disorders, such as heart failure and hypertension.

Hydrazono-5.beta., 14.beta.-androstane derivatives active on the

14-Deoxy-14.alpha.-cardenolides 3.beta.-thioderivatives and pharmaceutical compositions comprising same for treating cardiovascular disorders, such as heart failure and hypertension, are disclosed.

14-deoxy-14.alpha.-cardenolides 3.beta.-thioderivatives and

Digitoxigenin and dihydrodigitoxigenin 3.beta.-derivatives, a process for their preparation and pharmaceutical compositions containing same for the treatment of cardiovascular disorders such as heart failure and hypertension are disclosed.

Digitoxigenin and dihydrodigitoxigenin 3.beta.-derivatives and

17-hydroxyiminomethyl-14.beta.-hydroxy-5.beta. androstane derivatives, active on the cardiovascular system, a process for their preparation and pharmaceutical compositions thereof having the general formula ##STR1##

17-hydroxyiminomethyl-5-.beta., 14 .beta.-androstane derivatives active

A device for the continuous quantitative determination of glucose in the blood of a diabetic patient over a period of 24-36 hours, comprises a container for a saline solution with heparin, a microdialyzing needle inserted into a vein of a diabetic patient, a pump for injecting the solution into the microdialyzing needle, a semipermeable hollow fiber membrane located externally of the needle whereby dialysis occurs between the blood and the solution and only glucose and other substances of low molecular weight below 100,000 daltons go through the membrane and the concentration of the glucose and other substances of low molecular weight below 100,000 daltons inside the needle is proportional to that of the external side of the membrane. The needle is provided with an outgoing conduit, the conduit leads to a sensor, which comprises an enzymatic membrane coupled with a Platinum-Silver electrode. The glucose goes into the conduit, oxidation of glucose to gluconic acid and hydrogen peroxide occurs and the hydrogen peroxide is decomposed to give H.sub.2 O and oxygen with the liberation of two electrons whereby electric current is produced and the concentration of glucose in the blood is determined by determining the amount of current produced. It is possible to vary the dilution ratio of the fluid circulating inside the microdialyzing needle by varying the pump speed so that it is possible to have a ratio of the glucose containing saline solution to the actual concentration of glucose in the blood of 1/2-1/20.

Wearable artificial pancreas

Pharmaceutical compounds of the formula ##STR1## wherein R is H or CH.sub.3, R.sub.1 is H or OCH.sub.3, R.sub.2 is a C.sub.1 -C.sub.4 hydrocarbon group and X is an organic group. Also disclosed is a process for the preparation of these compounds. The compounds have dopamine agonist or antagonist activity.

D-nor-7-ergoline derivatives having anti-Parkinson and antipsychosis

Ergoline derivatives of the formula I ##STR1## wherein R.sub.1 =H,CH.sub.3 ; R.sub.2 =H, halogen, CH.sub.3, CN, C.sub.1 -C.sub.4 alkylthio or phenylthio; R.sub.3 =C.sub.1 -C.sub.4 hydrocarbon; R.sub.4 =H, OCH.sub.3 ; R.sub.5 =H and R.sub.6 =--CH.dbd.CH--CONHR.sub.7 or R.sub.5 and R.sub.6 =.dbd.CH--CONHR.sub.7 ; R.sub.7 =2-thiazolyl, 3-pyridazinyl, 1,3,4-thiadiazol-2-yl or 4-pyrimidinyl group optionally substituted, and pharmaceutically acceptable salts thereof, display activity on the Central Nervous System and are useful as antiprolactinic agents. Their preparation and pharmaceutical compositions containing them are also described.

Ergoline compounds useful as antiparkinson agents

Compounds of formula I: ##STR1## wherein R.sub.1 represents a hydrogen atom or a methyl group; R.sub.2 represents a hydrogen or halogen atom or a methyl, cyano, C.sub.1 -C.sub.4 alkylthio or phenylthio group; R.sub.7 and R.sub.8 represent hydrogen atoms and R.sub.3 represents a hydrogen atom or a methoxy group, or R.sub.7 represents a hydrogen atom and R.sub.3 and R.sub.8 taken together represent a bond, or R.sub.3 represents a hydrogen atom or a methoxy group and R.sub.7 and R.sub.8 taken together represent a bond; R.sub.4 represents a hydrocarbon group having from 1 to 4 carbon atoms; R.sub.5 represents a hydrogen atom or a hydrocarbon group having from 1 to 4 carbon atoms or a phenyl group; X represents an oxygen or sulphur atom or an imino group, R.sub.9 represents a hydrogen atom and B represents a cyano, a C.sub.2 -C.sub.5 alkoxycarbonyl or carbamoyl group, or R.sub.9 and B taken together represent a ##STR2## group wherein W represents an oxygen atom or an imino group; A represents a group of the formula CHR.sub.6, CH.sub.2 --CHR.sub.6 or CH.dbd.CR.sub.6 group wherein R.sub.6 represents a hydrogen atom or a C.sub.1 -C.sub.4 alkyl group; and n is 0, 1 or 2; and their pharmaceutically acceptable salts are disclosed, along with the use of these compounds as antiprolactinic and antihypertensive agents. The preparation of these compounds and pharmaceutical compositions containing them are also described.

Ergolines exhibiting protactin secretion inhibition activity

Growing community of inventors

Milan, Italy

Luigi Bernardi